Lilly's Kisunla receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
U.S. FDA approves Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Lilly's Mounjaro , a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes
Standard Uranium Announces Expansion of Davidson River Drill Program and Provides Update on Private Placement and LIFE Offering
